Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.31
  • Today's Change-0.55 / -2.92%
  • Shares traded1.45m
  • 1 Year change-35.19%
  • Beta0.9526
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

  • Revenue in USD (TTM)545.21m
  • Net income in USD-143.97m
  • Incorporated2001
  • Employees609.00
  • Location
    Arrowhead Pharmaceuticals Inc177 E Colorado Blvd, Suite 700PASADENA 91105United StatesUSA
  • Phone+1 (626) 696-4702
  • Fax+1 (626) 304-3401
  • Websitehttps://arrowheadpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Disc Medicine Inc0.00-116.49m1.97bn84.00--2.98-----3.92-3.920.0019.100.00----0.00-21.91---22.62--------------0.0414-------43.08------
CG Oncology Inc662.00k-105.56m2.04bn113.00--2.89--3,076.65-1.50-1.500.00959.250.001--2.665,858.41-16.15---16.56-------15,945.17------0.00--458.33---29.85------
Belite Bio Inc (ADR)0.00-42.55m2.06bn25.00--13.02-----1.36-1.360.004.860.00----0.00-32.07---32.07--------------0.00-------14.26------
Denali Therapeutics Inc0.00-453.94m2.11bn443.00--1.88-----2.67-2.670.007.730.00----0.00-31.83-16.91-33.90-19.81-------135.24----0.005---100.00---191.12---2.35--
Veracyte Inc463.39m33.05m2.12bn824.0064.651.7737.684.580.41890.41895.8615.260.36846.969.23562,370.102.63-4.192.77-4.4368.0266.827.13-13.704.78--0.00--23.4629.93132.44--32.57--
Beam Therapeutics Inc63.58m-387.34m2.13bn483.00--1.89--33.47-4.61-4.610.75811.170.045----131,631.50-27.41-24.98-31.01-29.69-----609.24-241.53----0.00---83.18412.30-184.28---6.50--
Agios Pharmaceuticals Inc37.04m665.99m2.26bn486.003.461.543.3761.0711.2911.290.644725.330.03080.175510.9076,203.7055.38-10.3857.88-11.0987.52--1,798.26-768.4017.93--0.00--36.07--291.35---32.66--
Apogee Therapeutics Inc0.00-205.39m2.27bn196.00--3.30-----3.59-3.590.0011.550.00----0.00-26.71---27.69--------------0.00-------116.88------
Recursion Pharmaceuticals Inc59.79m-574.78m2.29bn840.00--2.30--38.29-1.78-1.780.18922.300.0642--2.4571,178.57-61.70-42.93-69.79-48.716.50---961.32-828.92----0.0261--32.0090.93-41.33--28.49--
Xenon Pharmaceuticals Inc7.50m-251.45m2.47bn316.00--3.50--329.55-3.22-3.220.09609.190.009--1.5823,734.18-30.25-22.00-31.27-22.93-----3,352.61-1,082.36----0.00-------28.48--19.92--
Immunitybio Inc31.22m-409.10m2.48bn671.00------79.44-0.5517-0.55170.0421-0.69290.0886--3.1945,914.71-116.17-109.27-136.51-251.1252.72---1,310.55-11,599.512.05-2.584.08--2,270.5846.2729.09--9.95--
Arrowhead Pharmaceuticals Inc545.21m-143.97m2.53bn609.00--3.70--4.64-1.38-1.384.294.950.4312----895,252.90-12.23-35.54-13.87-42.61-----28.37-171.04---3.690.2859---98.52-53.80-192.04--63.79--
Crinetics Pharmaceuticals Inc760.00k-328.25m2.99bn437.00--2.38--3,935.80-3.82-3.820.008813.410.0007--0.09631,739.13-28.06-36.96-29.43-39.20-----43,191.05-7,785.98----0.00---74.11-2.73-39.10--50.86--
Data as of Jul 11 2025. Currency figures normalised to Arrowhead Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

54.20%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 202518.18m14.42%
The Vanguard Group, Inc.as of 31 Mar 202512.93m10.25%
Avoro Capital Advisor LLCas of 31 Mar 202511.11m8.81%
SSgA Funds Management, Inc.as of 31 Mar 20257.00m5.55%
Slate Path Capital LPas of 31 Mar 20255.23m4.15%
Fidelity Management & Research Co. LLCas of 31 Mar 20253.31m2.63%
UBS Asset Management Switzerland AGas of 31 Mar 20253.04m2.41%
Geode Capital Management LLCas of 31 Mar 20252.95m2.34%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20252.53m2.01%
Norges Bank Investment Managementas of 31 Dec 20242.05m1.63%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.